Michele Moschetta, MD PhD
机构: Executive Director, Early Clinical Development Oncology, AstraZeneca
每年引用次数
引用次数
引用: 6,690
H-指数: 52
I10-指数 : 86
出版物: 172
HIF-1 upregulation by IL-1 contributes to the migratory potential of breast cancer cells.
I Filippi , F Carraro , M Moschetta , R Giavazzi
52nd Annual Meeting of the Italian Cancer Society 70 -71
2010
Non-hypoxic induction of HIF-1 by interleukin-1 promotes cell migration in MDAMB231 breast cancer cells.
R Giavazzi , Antonella Naldini , Fabio Carraro , I Filippi
49 -49
2010
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
I Sahin , M Moschetta , Y Mishima , S V Glavey
Blood Cancer Journal 4 ( 4)
7
2014
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
S Berardi , A Caivano , R Ria , B Nico
Oncogene 31 ( 18) 2258 -2269
29
2012
Therapeutic targeting of the mTOR‐signalling pathway in cancer: benefits and limitations
M Moschetta , A Reale , C Marasco , A Vacca
British Journal of Pharmacology 171 ( 16) 3801 -3813
120
2014
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
S Manier , J T Powers , A Sacco , S V Glavey
Leukemia 31 ( 4) 853 -860
40
2017
Targeting vasculogenesis to prevent progression in multiple myeloma
M Moschetta , Y Mishima , Y Kawano , S Manier
Leukemia 30 ( 5) 1103 -1115
27
2016
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
M A Frassanito , L Rao , M Moschetta , R Ria
Leukemia 28 ( 4) 904 -916
53
2014
Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.
S V Glavey , A Naba , S Manier , K Clauser
Leukemia 31 ( 11) 2426 -2434
72
2017
Managing myelodysplastic symptoms in elderly patients.
ROBERTO Ria , M Moschetta , A Reale , G Mangialardi
Clinical Interventions in Aging 4 413 -423
34
2009
EXOME SEQUENCING REVEALS RECURRENT GERMLINE VARIANTS IN PATIENTS WITH FAMILIAL LYMPHOPLASMACYTIC LYMPHOMA
A Roccaro , A Sacco , J Shi , M Chiarini
HAEMATOLOGICA 101 567 -568
2016
Dynamics of neutrophils to lymphocyte ratio (NLR) predict outcomes of PD-1/PD-L1 blockade
MD Forster , M Moschetta , M Uccello , B Kasenda
BioMed Research International 2017
2017
CONCOMITANT DUAL ABLATION OF BLIMP1 AND P53 IN B-CELLS AS A NOVEL IN VIVO MODEL FOR HIGH-GRADE B-CELL LYMPHOMA
A Sacco , Y Kawano , M Moschetta , J Park
HAEMATOLOGICA 102 557 -557
2017
TARGETING THE CXCR4/SDF1 AXIS IN B-CELL LYMPHOPROLIFERATIVE DISORDERS
A Sacco , M Moschetta , Y Kawano , Y Mishima
HAEMATOLOGICA 101 S10 -S11
2016
IN VIVO TARGETING OF STROMAL-DERIVED FACTOR-1 AS A STRATEGY TO PREVENT MYELOMA CELL BONE TO BONE DISSEMINATION
A Roccaro , A Sacco , M Moschetta , Y Mishima
HAEMATOLOGICA 99 247 -248
2014
IN VIVO TARGETING OF STROMAL-DERIVED FACTOR-1 AS A STRATEGY TO PREVENT MYELOMA CELL DISSEMINATION TO DISTANT BONE MARROW NICHES
A Roccaro , A Sacco , M Ungari , S Lonardi
HAEMATOLOGICA 98 226 -226
2013
A NOVEL ACTIVATING SOMATIC MUTATION OF CXCR4 PLAYS A CRUCIAL ROLE IN MODULATING WALDENSTROM MACROGLOBULINEMIA BIOLOGY
A Roccaro , A Sacco , C Jimenez , P Maiso
HAEMATOLOGICA 99 502 -503
2014
TARGETING EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) THROUGH CXCR4 BLOCKADE IN MULTIPLE MYELOMA
A Roccaro , A Sacco , M Moschetta , J Shi
HAEMATOLOGICA 100 177 -177
2015
719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
M Moschetta , T Doi , Y Kuboki , R Sundar
Annals of Oncology 34 S496 -S496
1
2023
The AP-1 Family Member JunB: A Novel Potential Target for Therapy in Multiple Myeloma
M Moschetta , A Sacco , AM Roccaro
Am J Leuk Res. 2017; 1 (1) 1004